Cetera Advisor Networks’s Theriva Biologics TOVX Stock Holding History

Cetera Advisor Networks’s Portfolio TOVX Stock Details TOVX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-1	Closed	-$3K	–	1156
2018 Q2	$3K	Hold	1	–	–	﹤0.01%	836
2018 Q1	$4K	Hold	1	–	–	﹤0.01%	849
2017 Q4	$6K	Hold	1	–	–	﹤0.01%	988
2017 Q3	$10K	Hold	1	–	–	﹤0.01%	914
2017 Q2	$6K	Hold	1	–	–	﹤0.01%	920
2017 Q1	$7K	Hold	1	–	–	﹤0.01%	917
2016 Q4	$8K	Buy	+1	New	+$10.3K	﹤0.01%	864

Other funds holding TOVX

Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

TSS

Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return

LTFS

Ladenburg Thalmann Financial Services Miami, Florida $15.9B AUM 25.16% 1-Year Est. Return

Cetera Advisor Networks's TOVX Position: Q3 2018 in Review

Cetera Advisor Networks sold out of Theriva Biologics (TOVX) in Q3 2018, closing a stake of 1 share — an estimated $3K sold.

Cetera Advisor Networks first reported a position in TOVX in Q4 2016 and held it in 7 quarters. The position peaked at $10K in Q3 2017. 22 funds tracked by Wall St. Rank hold TOVX as of Q3 2018.

Cetera Advisor Networks reported no remaining Theriva Biologics position as of Q3 2018 after selling out during the quarter.
Cetera Advisor Networks sold 1 Theriva Biologics share in Q3 2018, an estimated $3K.
Cetera Advisor Networks first reported a position in Theriva Biologics in Q4 2016 and held it in 7 quarters.
Cetera Advisor Networks's Theriva Biologics position peaked at $10K in Q3 2017.
22 funds tracked by Wall St. Rank held Theriva Biologics as of Q3 2018.

Based on Cetera Advisor Networks's 13F filing for Q3 2018, filed 14 Nov 2018.